Background and Aim: Sorafenib is recommended as a standard treatment for advanced hepatocellular carcinoma (HCC). The efficacy and safety of sorafenib as a first-line therapy in Korean patients with advanced HCC were investigated. Methods: From 2007 to 2012, 86 patients with advanced HCC (Barcelona Clinic Liver Cancer stage C) treated with sorafenib as a first-line therapy were enrolled from five tertiary hospitals. Predictors of overall survival (OS) and progression-free survival (PFS) were analyzed. Results: The median age was 59.5 years, and 71 (82.6%) were males; 57 (66.3%) patients were in Child-Pugh class A. The median OS and PFS were 5.0 (range 4.0-5.9) and 3.2 (range 2.6-3.7) months, respectively. Regarding OS, Child-Pugh class A (6.0 vs 2.8 months), tumor diameter <5cm (6.0 vs 4.3 months), baseline α-fetoprotein <200ng/mL (5.8 vs 4.1 months), and the advent of hand-foot-skin reaction of ≥grade 2 (5.9 vs 4.0 months) were independent favorable predictors (all P<0.05). Similarly, regarding PFS, Child-Pugh class A (4.3 vs 2.1 months), tumor diameter <5cm (3.9 vs 2.8 months), baseline α-fetoprotein <200ng/mL (5.6 vs 2.8 months), and the advent of hand-foot-skin reaction of ≥grade 2 (4.5 vs 2.6 months) were independent favorable predictors (all P<0.05). All toxicities during sorafenib treatment were manageable. Conclusions: Because the efficacy of sorafenib seems marginal in Korean patients with treatment-naïve HCC, how to select candidates with favorable outcomes should be further investigated.
|Number of pages||7|
|Journal||Journal of Gastroenterology and Hepatology (Australia)|
|Publication status||Published - 2014 Jul|
All Science Journal Classification (ASJC) codes